Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Study: Generic Semaglutide Production Costs Just $3 Monthly
New research reveals generic semaglutide manufacturing costs could drop to $3 per month in Canada, representing massive savings from current $400 prices.
Health Canada Eyes Summer 2026 Generic Semaglutide Approvals
Radio-Canada International reports Health Canada reviewing nine generic semaglutide submissions with summer 2026 approval timeline expectations for Canadian patients.
Canada's Drug Agency to Decide Mounjaro Coverage Within Weeks
Canada's Drug Agency expected to announce public plan coverage decision for Eli Lilly's Mounjaro within weeks, affecting provincial formulary access.
Alberta Blue Cross Reports Second Wave GLP-1 Innovation for 2026
Alberta Blue Cross drug pipeline report highlights improved formulations and expanded applications driving continued GLP-1 therapy growth in 2026.
Novo Nordisk Launches $199 Introductory Price for Low-Dose GLP-1s
Novo Nordisk introduces $199 monthly pricing for starter doses of Wegovy and Ozempic in Canada, expanding access ahead of generic competition.
Hims & Hers Launches Canadian Operations Ahead of Generic GLP-1s
US telemedicine company Hims & Hers expands into Canada as the country prepares for generic semaglutide availability starting mid-2026.
GLP-1 Drugs Drive Major Canadian Employer Drug Plan Cost Increases
New Benefits Canada report reveals GLP-1 medications are a major driver of employer drug plan cost increases in 2026 despite expected generic approvals.
Canada's Drug Agency Estimates Wegovy Costs $5,000 Annually
Canada's Drug Agency releases official annual cost estimate of $5,000 for Wegovy based on recommended maintenance dose, providing new government costing data.
Generic Semaglutide Could Cut Canadian Drug Costs by 65%
Benefits industry analysis projects 65% price reduction for generic semaglutide in Canada as Health Canada reviews nine applications from manufacturers.
Health Canada Adds Submission Class Data to Drug Review Tracker
Health Canada enhanced its public drug review tracker on March 20, 2026, adding submission class information to help Canadians track generic applications.
GLP-1 Drug Costs Could Drop from $400 to $15 Monthly in Canada
Current $300-400 monthly costs for Ozempic and Wegovy could fall to $15 with generic competition, representing a 96% price reduction for Canadian patients.
Generic Semaglutide Manufacturing Begins at Canadian Facilities
Canadian pharmaceutical companies have begun production of generic semaglutide at domestic manufacturing facilities ahead of regulatory approvals.
Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada expands Rybelsus approval to reduce major cardiovascular events in adults with Type 2 diabetes and heart disease risk factors.
Health Canada May Approve First Generic Semaglutide May-September
Industry sources indicate Health Canada could approve the first generic semaglutide between May and September 2026, marking a narrower timeline than previous estimates.
Dr. Reddy's, Sun Pharma Apply for Generic Semaglutide in Canada
Two major Indian pharmaceutical companies have submitted applications to Health Canada for generic semaglutide approval, joining the competitive race.
Generic Ozempic Approvals Expected Spring 2026 in Canada
Industry experts predict Health Canada will approve first generic semaglutide applications by spring 2026, with multiple approvals expected by year-end.
Aspen Pharma Targets Q3 2026 Generic Semaglutide Launch
Aspen Pharmacare sets specific third quarter 2026 target for generic semaglutide launch in Canada, joining nine companies seeking Health Canada approval.
Vimy Pharma to File Generic Semaglutide Application Soon
Edmonton-based Vimy Pharma expects to submit its Health Canada application for generic semaglutide within weeks, joining eight other companies in review.
Health Canada Adds Submission Class Data to Public Tracker
Health Canada's drug review tracker now shows submission 'class' details including Access Consortium reviews as of March 20, expanding transparency.
Eli Lilly Cuts U.S. Zepbound Price Following Canada Reductions
Eli Lilly reduces U.S. Zepbound pricing for single-dose vials after cutting Canadian prices 20% in December, expanding affordability strategy globally.
Pfizer Develops Long-Acting GLP-1 Drug to Challenge Market
Pfizer is developing a long-acting GLP-1 drug that could compete directly with Eli Lilly's Mounjaro and Zepbound when it reaches the Canadian market.
Health Canada Adds New Tracking Features for Generic Reviews
Health Canada's March 20 update to drug review tracking now shows submission class and Access Consortium status for all completed reviews including generics.
3 Million Canadians Use GLP-1 Drugs, Survey Reveals High Demand
New survey data shows approximately 3 million Canadian adults currently take GLP-1 medications like Ozempic and Mounjaro, with many more seeking access.
India Launches Generic Semaglutide at $14 Monthly This Weekend
India becomes first major market to launch generic semaglutide at $14 monthly, with 50 brands expected as Canada awaits Health Canada approvals for nine applications.
Generic Semaglutide Could Cost Just $15 Monthly Worldwide
New reports indicate generic semaglutide could be priced as low as $15 monthly or $3 per dose globally, significantly undercutting current brand prices.
Novo Nordisk Considers Renamed Ozempic to Fight Generics
Novo Nordisk explores launching a lower-priced, renamed version of Ozempic in Canada as nine generic semaglutide applications undergo Health Canada review.
Health Canada Approves Heart Protection for Rybelsus Pill
Health Canada approves new cardiovascular indication for Rybelsus semaglutide pill, making it first oral GLP-1 with heart protection approval in Canada.
PharmaTher Joins Generic Semaglutide Race in Canada
PharmaTher launches strategic initiative to pursue Health Canada approval for generic semaglutide as regulatory exclusivity ended in January 2026.
Provinces Await Health Canada Approval Before Generic Coverage
Most provinces tell insurers they're waiting on Health Canada approvals before deciding coverage policies for generic semaglutide medications.
Health Canada's 180-Day Generic Review Beats Global Timelines
Health Canada's 180-day generic drug review timeline is shorter than similar regulatory agencies worldwide, potentially accelerating generic GLP-1 approvals.
Public Plans Should Cover Generic GLP-1s, Expert Says
Healthcare expert recommends public insurance plans cover generic semaglutide when available, citing accessibility benefits. Latest from GLP1Prices.ca
Novo Nordisk Cuts Wegovy Cash Price to $349 Monthly in Canada
Novo Nordisk announces new $349 monthly cash price for Wegovy in Canada, representing significant reduction from previous pricing - GLP1Prices.ca
Health Canada Issues Counterfeit GLP-1 Drug Warning
Health Canada warns Canadians about fake semaglutide and tirzepatide products as demand grows. Get the latest on GLP1Prices.ca
Health Canada Sets 180-Day Review Timeline for Generic GLP-1s
Health Canada confirms 180-day target timeline for reviewing nine generic semaglutide applications currently under regulatory assessment. GLP1Prices.ca
Retatrutide Triple Agonist Drug Enters Phase 3 Trials in Canada
Health Canada has not yet approved retatrutide, but the experimental triple agonist GLP-1 medication is advancing through clinical trials - GLP1Prices.ca
Health Canada Issues Notice of Compliance for New Wegovy Indication
Health Canada granted Notice of Compliance under NOC/c policy for new Wegovy indication in January 2026. Latest regulatory updates at GLP1Prices.ca
Vimy Pharma Plans Canadian-Made Generic Semaglutide Filing
Vimy Pharma expects to file generic semaglutide application with Health Canada in coming weeks, joining nine other companies. Latest on GLP1Prices.ca
FDA Approves Oral Wegovy 25mg as First Weight Management Pill
FDA approved Novo Nordisk's oral Wegovy 25mg in December 2025 as first oral GLP-1 for weight management. Canadian approval timeline at GLP1Prices.ca
Generic Semaglutide to Test Canadian Employer Drug Budgets
Canadian employers face drug plan budget pressures as generic semaglutide launches mid-2026 with expected 65% price cuts. Coverage at GLP1Prices.ca
Alberta Blue Cross Delays Generic Semaglutide Launch to Mid-2026
Alberta Blue Cross reports generic semaglutide launch delayed until mid-2026, affecting employer drug plan cost relief expectations. Track updates at GLP1Prices.ca
Health Canada Tracker Shows 9 Generic Semaglutide Reviews
Health Canada's new public tracker reveals status of nine generic semaglutide applications under review, providing transparency - GLP1Prices.ca
Lilly Finds Impurity in Compounded Tirzepatide Products 2026
Eli Lilly reports impurities in compounded versions of tirzepatide, raising safety concerns for Canadian patients using non-authorized products. GLP1Prices.ca
Canada's Drug Agency to Decide Mounjaro Public Coverage
Provincial health plans await recommendation on Mounjaro coverage as assessment nears completion. Latest updates at GLP1Prices.ca
Novo Nordisk Forecasts Sales Slowdown from Generic Competition
Novo Nordisk officially acknowledges that generic semaglutide competition will slow Canadian sales growth as nine manufacturers prepare market entry. GLP1Prices.ca
Semaglutide Sales Hit $3.5 Billion in Canada During 2025
IQVIA Canada data reveals total 2025 semaglutide sales reached $3.5 billion across all brands as generic competition begins. Track prices at GLP1Prices.ca
Generic Semaglutide Production Begins in Canadian Facilities
Canadian pharmaceutical companies have started manufacturing generic versions of semaglutide following patent expiry. Track prices at GLP1Prices.ca
WHO Conditionally Recommends GLP-1s for Obesity Treatment 2026
World Health Organization issues conditional recommendation for GLP-1 therapies in obesity treatment, impacting Canadian regulatory decisions. GLP1Prices.ca
Felix Health Launches Generic Semaglutide Waitlist in Canada
Canadian telehealth provider Felix for Health opens waitlist for generic semaglutide as Health Canada reviews nine applications. GLP1Prices.ca
Health Canada Approves Wegovy for MASH Treatment in 2026
Health Canada issues Notice of Compliance for Wegovy semaglutide injection for MASH indication under NOC/c policy - GLP1Prices.ca
Novo Nordisk Launches Plosbrio and Poviztra Brands in Canada
Health Canada approves two new semaglutide brand names as Novo Nordisk expands product portfolio ahead of generic competition. GLP1Prices.ca
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada